Vol. 40 No. 6 (2023): Diciembre
Antimicrobial

Profile of tigecycline use in a university hospital in Chile

Roberto Olivares Castillo
Hospital Clínico Universidad de Chile
Bio
Paulina Pérez Andrade
Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile
Bio
Roberto Olivares Castillo
Hospital Clínico Universidad de Chile
Bio
Fernanda Áila O
Hospital Clínico Universidad de Chile
Bio
Matilde Lagos Peña
Hospital Clínico Universidad de Chile
Bio
Mario Luppi Norambuena
Hospital Clínico Universidad de Chile
Bio
Jeannette Dabanch Peña
Hospital Clínico Universidad de Chile
Bio
Francisco Silva Ojeda
Hospital Clínico Universidad de Chile
Bio
Cover V40 n6

Published 2023-12-23

How to Cite

1.
Olivares Castillo R, Pérez Andrade P, Olivares Castillo R, Áila O F, Lagos Peña M, Luppi Norambuena M, Dabanch Peña J, Silva Ojeda F. Profile of tigecycline use in a university hospital in Chile. Rev. Chilena. Infectol. [Internet]. 2023 Dec. 23 [cited 2025 Nov. 25];40(6). Available from: https://revinf.cl/index.php/revinf/article/view/1853

Abstract

Background: The use of tigecycline has been increasing in recent years, due to increase in bacterial resistance and the scarcity of therapeutics alternatives. Aim: To characterize and evaluate the tigecycline prescriptions of patients hospitalized in a university hospital, during the years 2017 and 2018.  Methods: A retrospective observational study was carried out, where the patients, the therapies, the associated microbiology, the clinical outcomes and the adverse reactions associated with tigecycline were characterized. The proportion of appropriate prescriptions was determined by committee of experts and the consumption of tigecycline measure in DDD/100 bed-days. Results: 89 patients who used tigecycline were characterized, of which 67 (75.3%) met the selection criteria. 53.7% of the patients were male, with a mean age of 60 +/- 15 years The main reason for hospitalization was surgical (65.7%).  67.1% of the treatments with tigecycline were started in a critical patient unit and the predominant focus of the infection was the abdomen (64.3%).  50% of the therapies with tigecycline were ordered according to the identified microbiology. In 65.7% of the cases, tigecyclin was used as monotherapy at the usual dose (62.9%).  Nausea (8.6%), diarrhea (7.1%) and vomiting (4.3%) were the most reported adverse events. 84.3% of the treatments were considered appropriate. In 2017, 0.4 DDD/100 bed/days were consumed and 0.6 DDD/100 bed/days in 2018, with de ICU being the service that presented the highest use in both years. Discussion: Based on the results obtained, tigecycline was mainly used as monotherapy for the treatment of intra-abdominal infections in patients hospitalized for surgical reasons in a critical patient unit at the usual doses of 100 mg loading followed by 50 mg every 12 hours IV. In 50% of the case the therapy was directed according to microbiology. The most common adverse events were gastrointestinal. Conclusion: Most of the prescribed therapies were considered appropriate by the expert committee.